Edition:
United States

Innate Pharma SA (IPH.PA)

IPH.PA on Paris Stock Exchange

11.28EUR
7:04am EDT
Change (% chg)

€0.36 (+3.30%)
Prev Close
€10.92
Open
€10.98
Day's High
€11.43
Day's Low
€10.97
Volume
149,452
Avg. Vol
358,665
52-wk High
€15.83
52-wk Low
€8.26

IPH.PA

Chart for IPH.PA

About

Innate Pharma SA is a France-based biopharmaceutical Company that develops drugs for treatment of cancer and inflammatory diseases. The Company identifies and characterizes drug candidates, selects indications and manages the pre-clinical and clinical development of products. Innate Pharma primarily focuses on the development of... (more)

Overall

Beta: 1.07
Market Cap(Mil.): €588.76
Shares Outstanding(Mil.): 53.92
Dividend: --
Yield (%): --

Financials

  IPH.PA Industry Sector
P/E (TTM): 46.56 58.01 30.10
EPS (TTM): 0.23 -- --
ROI: 5.61 0.27 13.21
ROE: 15.98 6.15 14.37

BRIEF-Innate Pharma expands Phase I/II trial testing lirilumab with Opdivo

* Announces the expansion of Phase I/II trial evaluating lirilumab in combination with Opdivo Source text for Eikon: Further company coverage: (Gdynia Newsroom)

Mar 13 2017

CORRECTED-BRIEF-Innate Pharma FY operating result turns to profit of 7.6 million euros

* Cash and cash equivalents at December 31, 2016 230.7 million euros ($244.47 million) versus 273.7 million euros year ago

Mar 07 2017

BRIEF-Innate Pharma: Cash and cash equivalents at Dec. 31, 2016 of 230.7 million euros

* Cash and cash equivalents at Dec. 31, 2016 230.7 million euros ($244.27 million) versus 152.9 million euros year ago

Mar 07 2017

BRIEF-Innate Pharma announces top-line results from EffiKIR trial

* Innate Pharma announces top-line results from EffiKIR trial evaluating the efficacy of lirilumab

Feb 06 2017

BRIEF-Innate Pharma receives $15 million milestone payment from Bristol-Myers Squibb

* Innate Pharma receives $15 million milestone payment from Bristol-Myers Squibb

Jan 09 2017

AstraZeneca oncology head jumps ship to become Innate CEO

LONDON AstraZeneca is losing its head of oncology, Mondher Mahjoubi, who is departing to lead French biotech company Innate Pharma.

Dec 19 2016

French cancer specialist Innate Pharma can remain independent, for now: CEO

PARIS France's Innate Pharma believes that its cash position and portfolio are sufficiently robust for the cancer drug company to remain independent for the time being and will seek co-development deals modeled on an agreement struck with AstraZeneca in April.

Nov 25 2016

BRIEF-Innate Pharma interim phase 1/2 data for lirilumab in combination with opdivo (nivolumab)

* Reported on Saturday interim phase 1/2 data show encouraging clinical benefit for lirilumab in combination with opdivo (nivolumab)

Nov 14 2016

BRIEF-Innate Pharma preliminary phase 1/2 efficacy data

* Preliminary phase 1/2 efficacy data of lirilumab in combination with opdivo (nivolumab)

Nov 08 2016

BRIEF-Innate pharma Q3 revenue up to 11.2 million euros

* Q3 cash, cash equivalents and financial assets amounting to 239.6 million euros ($266.29 million)

Nov 03 2016

More From Around the Web

Earnings vs. Estimates